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this study, we undertook targeted metabolomic analyses of nucleotides in different cancer cell culture
models using a sensitive and reproducible ion-pair HPLC method. The experimental data were analyzed
by principal component analysis (PCA) to identify potential biomarkers in cancer cells, and statistical
signiﬁcance was determined by one-way analysis of variance. As a result, a clear differentiation of normal
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Targeted metabolic analysis of nucleotides in tumor cells 255cells. Six variables (AMP, UDP, CTP levels with a signiﬁcance of Po0.05; ATP, UTP and GMP levels
with a signiﬁcance of Po0.01) were considered as potential biomarkers; the content of AMP, UTP, GMP
and ATP was signiﬁcantly higher in cancer cells. The receiver operating characteristic (ROC) curve
analysis allowed us to discriminate normal cells from tumor cells based on area under the curve (AUC).
The sequence of their AUC values were: ATP (0.979)4UTP (0.938)4CTP¼GMP (0.896)4AMP
(0.812)4UDP (0.792), so we conclude that ATP and UTP are the best potential biomarkers in tumor
cells. This study may provide a valuable tool for studying minute alterations of intracellular nucleotide
pools induced by anticancer/antiviral drugs, diseases or environmental factors.
& 2013 Institute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical
Association. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
It is widely accepted that signiﬁcant metabolic changes take place
when cells are transformed from normal to malignant, and that some
metabolic events facilitate the process of tumor invasion and metastasis
to distant organs. The change in levels of RNA and DNA is considered
to play a crucial role in the processes1,2. Nucleotides participate in
many biochemical processes as activated precursors and source of
energy in DNA and RNA biosynthesis, and as intermediate products
for synthesis of lipids and proteins. A metabolic change in nucleotide
concentrations occurs during carcinogenesis. For example, alterations
in ATP concentration can indicate the energy status of the tumor.
Recent studies described ATP as a useful biomarker for some
diseases3–5. For instance, Scherer et al.6 found that levels of ATP
and ADP were signiﬁcantly increased in cerebrospinal ﬂuid of adult
rats with chronic mild hyperhomocysteinemia, while AMP and
adenosine were decreased. The adenine nucleotides, i.e., AMP, ADP,
ATP and adenosine, are signaling molecules related to the modulation
of immune responses in cancers7. Other important molecules affecting
the glycosylation process are the ribonucleotide triphosphates, includ-
ing UTP, CTP, GTP and ATP; they are the driving forces for cell
growth and energy metabolism, are involved in numerous cellular
processes, and have wide regulatory potential8. The importance of
other nucleotides still remains largely unexplored, as indeed does their
precise role in the pathophysiology or physiology of systems. Thus,
changes in nucleotide composition are an extremely important part of
metabolomics, and knowledge of their changes is a prerequisite for
establishing reliable cellular models. Recently, researchers reported that
various metabolic perturbations induced by pharmaceuticals9–12 and
environmental factors13–16 observed in cancers interfered with the
biosynthesis of DNA/RNA or their precursors in cancers.
Nevertheless, most cancer diseases have a long asymptomatic
period and are difﬁcult to detect in the early stages by traditional
clinical tools. There is currently a lack of highly sensitive and
speciﬁc clinical diagnostic tools. Metabolomics is a relatively new
ﬁeld in genomics research but it is gaining broader recognition in
the cancer community17,18, as it can detect subtle changes in
metabolic pathways and shifts in homeostasis before phenotypic
changes are evident. Similar to genomics or proteomics, metabo-
lomics generates a large volume of specialized data, which can be
used to elucidate metabolic alterations associated with a particular
biological process that occurs downstream from genomic or
proteomic changes. As these processes precede changes in cell
morphology, they may be useful to predict the occurrence and
development of diseases. Metabolomic technologies have been
proved useful for identifying tumor-associated metabolites which
are of value in following course of a disease, and therefore maypermit early disease diagnosis and real-time monitoring of a
disease or a therapeutic intervention.
In metabolomic research, systemic bioﬂuid, such as serum/plasma
and urine, is most commonly used as obtaining these biological
substances is relatively noninvasive and convenient. But the results
obtained from these bio-samples should be integrally considered to
represent the metabolic homeostasis of the whole body rather than the
local pathogenic tissues. Metabolites in tissues reﬂect the perturbed
metabolism more precisely and effectively for the prognosis or
diagnosis of a disease than systemic bioﬂuids19. However, biomarkers
identiﬁed in animal tissues are not necessarily the same as in humans
due to species differences. Cultured cells from human sources such as
humanized cell models help to avoid these interferences and have
yielded intriguing results20. Since tumor cells have a unique metabolic
phenotype21, they are signiﬁcantly different in metabolism including a
redistribution of metabolic networks22. These metabolic changes result
in different metabolic landscapes in cancer cells versus normal cells.
Thus, metabolomics may be the ideal tool for early diagnosis of cancer.
Grifﬁn et al.23 discussed some clinical markers in oncology, such as
nucleosides that increased in glioma cells during apoptosis. Moreover,
intracellular endogenous nucleosides are a target of numerous nucleo-
side analogs and antiviral drugs which interfere with the synthesis of
DNA and RNA. For example, exposure of hormone-responsive
Ishikawa human endometrial adenocarcinoma cells to tamoxifen
resulted in dose-dependent changes in nucleotides, suggesting that
tamoxifen modiﬁes RNA translation23.
Numerous experimental investigations have shown that metabolism
in normal and tumor cells is different. In 1924, Warburg24 observed
that most cancer cells predominantly produced lactic acid and energy
by a high rate of glycolysis; they had poor ‘ox-phos’ capacity and
produced high level of H2O2 in the presence of O2. The high glycolytic
activity of cancer cells was essential for their survival as it prevented
cell death induced by ATP depletion and H2O2 accumulation
24.
Current techniques for identifying metabolic differences between tumor
and normal cells include non-invasive imaging technologies, and are
used in cancer diagnosis and therapy25. These differences between
normal cells and tumor cells can also act as a biochemical foundation
for the development of therapeutic strategies to preferentially kill
malignant cells26–28. Zhang et al.12 used an LC–MS method to measure
ribonucleotide (RN) and deoxyribonucleotide (dRN) pool sizes in
PANC1, H1975, HepG2 and H23 cells; as anticipated, they found that
the levels of RNs in all the cell lines were signiﬁcantly greater than that
of dRNs, and that the pool sizes varied from one cell line to another.
These results are consistent with results previously described by
Huang29.
Over the last several decades several analytical methods have been
proposed for the quantitation of these small molecules, such as
C. Zhang et al.256capillary electrophoresis30, hydrophilic interaction chromatography31,
enzyme assay32 and LC–MS33,34. A classical liquid chromatography
system with UV detection based on an ion-pairing reagent and non-
volatile high salt concentration in mobile phase was well established
and successfully applied to quantify nucleotides26,35–38. Contreras-Sanz
et al.35 used the ion-pair HPLC method for the determination of 12
nucleosides in renal epithelial cells and in human urine samples. Jia
et al.36 and Huang et al.29 described an ion-pair HPLC method for
quantiﬁcation of eight nucleotide-triphosphate levels in HepG2 and in
16 normal and tumor cells. van Moorsel et al.37 analyzed the levels and
metabolism of four nucleotide triphosphates in 21 solid tumor cells.
However, only a few studies have reported the simultaneous determi-
nation of nucleoside mono-, di- and triphosphates in cell buffers based
on ion-pair reverse phase chromatography.
In this study, liquid chromatography coupled with UV detection
using tetrabutylammonium hydroxide as ion-pairing agent was
developed and validated to quantitate mono-, di- and tri-phosphate
nucleosides in 6% trichloroacetic acid-treated cell extracts. The
aim was to develop a reliable, simple and reproducible method for
quantifying up to 12 nucleotides and determine whether there is
difference in nucleotide levels between normal cells and tumor
cells. Biologically relevant biomarkers of cancer cells were also
identiﬁed by examining the relationship between metabolites in
normal cells and in tumor cells.2. Materials and methods
2.1. Chemicals
All standards (ATP-Na2, dUTP-Na3, CTP-Na2, UTP-Na, dATP-
Na3, dGTP-Na4, dCTP-Na3, GDP-Na2, GMP-Na2, UDP-Na2,
ADP-Na2, AMP-Na2) were purchased from Sigma-Aldrich (St.
Louis, MO, USA). All solvents and reagents for sampling and
chromatographic analysis (HPLC grade) were purchased from
Tianjin Bodi Chemical Holding Co., Ltd. and Shandong Yuwang
Industrial Co., Ltd., respectively. Roswell Park Memorial Institute
(RPMI) 1640 media, Dulbecco's modiﬁed Eagle's cell culture
media (DMEM), fetal calf serum (FCS) and 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) were purchased from
Gibco-BRL (Grand Island, USA). Trypsin was obtained from
Amresco LLC (Solon, USA). Phosphate-buffered saline (PBS) was
prepared in our laboratory.
2.2. Instruments
Analyses were performed on an Elite-L2130 HPLC system
(Hitachi Technologies, Japan) consisting of a binary solvent
delivery system, a column temperature controller and an Elite-
L2400 UV detector. A Synergi Hydro C18 column (250 mm 4.6
mm, 4.0 μm) equipped with a Synergi Hydro C18 Security guard
column (Phenomenex, Guangzhou, China) was used for chroma-
tographic separation by gradient elution. The mobile phase
consisted of two buffers. Buffer A was 25% MeOH contained
50 mM KH2PO4 and 5 mM tetrabutylammonium hydroxide neu-
tralized to pH 6.9 with 1 M NaOH; buffer B was water contained
10 mM KH2PO4 and 8 mM tetrabutylammonium hydroxide
adjusted to pH 6.9 with 1 M HCl. Both solutions were freshly
prepared and ﬁltered through a 0.45 μm ﬁlter and stored at 4 1C.
The buffers were degassed by sonication for at least 20 min before
use. Gradient was set as follows: 0–50 min, 48–60% A; 50–
68 min, 60–100% A; 68–77 min, 100% A. The ﬂow rate was keptat 0.8 mL/min and samples of 20 μL were injected for analysis.
The UV detector absorption wavelength was set at 254 nm and the
column temperature was ambient.
2.3. Preparation of standard solutions
A primary stock solution of each standard was prepared by
dissolving 12 standards in MeOH-H2O (1:1, v/v). The concentra-
tion (mg/mL) for each stock solution was 1.010 (ADP), 1.006
(AMP), 1.002 (UDP), 0.998 (GDP), 0.998(GMP), 1.050 (CTP),
0.876 (dCTP), 1.070 (UTP), 0.5722 (dGTP), 1.068 (dUTP), 1.032
(ATP) and 0.805 (dATP). All stock solutions were stored at
−20 1C. They were successively diluted with ultrapure water to
prepare series of working solutions for a calibration curve. For
each experiment, serial dilutions of all standards were freshly
prepared. All solutions were ﬁltered through 0.22 μm ﬁlters and
then an aliquot of 20 μL was loaded for HPLC analysis. Duplicate
injections were performed for all assays.
2.4. Cell culture condition
All cell lines were kept in our laboratory. The hepatoma cells
(HepG2), human ovarian carcinoma cells (SKOV3), human
pulmonary carcinoma cells (A549), human breast adenocarcinoma
cells (MCF7), human breast carcinoma cells (T47D), human
rhabdomyosarcoma cells (A204), human hepatic stellate cells
(LX2), human mammary epithelial cells (MCF10A), human
kidney mesangial cells (HRMC) and preadipocyte cells (3T3L1)
were cultured in DMEM medium. Human mouth epidermal
carcinoma cells (KB), human gastric carcinoma cells (SGC7901),
Henrietta Lacks strain of cancer cells (HeLa), human prostate
carcinoma cells (PC3), human prostate cancer cells (DU145) and
human ﬁbrosarcoma cells (HT1080) were cultured in RPMI 1640
medium. Both DMEM and RPMI 1640 medium contained 2 g/L
NaHCO3 and 2.4 g/L HEPES supplemented with 10% FCS,
penicillin (100 U/mL) and streptomycin (100 μg/mL). Cells were
grown in a humidiﬁed incubator at 37 1C and 5% CO2/95% O2
atmosphere. Media was refreshed every 48 h. All cell lines were
harvested in their exponential growth phase. A hemacytometer was
used to count the number of adherent cells after digestion with
0.25% trypsin–EDTA solution.
2.5. Cell extraction
At the end of the incubation, the medium in each culture dish was
discarded and the adherent cells were quickly rinsed twice with ice-
cold PBS. The cells were harvested by fast trypsinization at different
times (3–4 min at 37 1C in a CO2 incubator). After suspension in
culture medium with 10% FCS, they were carefully counted under a
microscope. Nucleotides extracts were obtained using trichloroacetic
acid as previously described29,36,39. The following extraction steps
were performed on ice: The cells were washed twice with ice-cold
1PBS and centrifuged at 1000 rpm for 5 min at 4 1C. The
supernatant was discarded and 150 μL of 6% TCA was added to
precipitate proteins. The mixture was vortexed for 20 s, chilled on
ice for 20 min, vortexed for another 20 s, and centrifuged for 10 min
at 14,000 rpm at 4 1C. The resulting supernatant was transferred to a
new 1.5 mL tube. All samples were either stored at −80 1C or
directly analyzed after being neutralized by adding 0.5 M KOH. The
neutralized solution was ﬁltered through a 0.22 μm ﬁlter and loaded
onto the column for analysis.
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Speciﬁcity was assessed by running samples with single analyte
versus that containing all analytes of interest and interference of
the extracting agent was analyzed. The calibration curve of the
individual standards was performed using six known concentra-
tions by plotting peak areas against the concentration of analytes.
The LOD was the concentration with a signal-to-noise ratio (S/N)
of 3, whereas the LOQ was determined at S/N¼10. The precision
of the method was analyzed using a series of standard solutions at
low, medium and high concentrations. For the intra- and inter-day
precision, the relative standard deviations (% RSD) of three
concentrations of standard solutions were analyzed three times
on a single day and on three consecutive days, respectively.
Twelve nucleotides were endogenously present in cells, so
blank cell extracts could not be obtained. Moreover, preliminary
experiments showed that the protein precipitating agent (TCA) did
not have a degradative effect on nucleotides. To assess the
accuracy of the method in this study, the recovery was determined
by adding low, medium and high concentrations into a selected
cell extract pool with known concentrations of the analytes29,36.
Measured concentrations were calculated from the peak areas and
the relevant calibration curves. Recoveries were deﬁned by the
following calculation: (observed value-endogenous value)/added
value 100%. Stability was evaluated after sample solutions were
stored for 0, 2, 4, 8, 12 and 24 h at room temperature.
2.7. Data analysis and statistics
The intracellular concentration of each nucleotide was calculated
based on the standard curves. Principal component analysis (PCA)
between normal cell and tumor cell samples was performed using
SIMCA-P 11.5 software (Umetrics, Sweden). One-way analysis of
variance signiﬁcance test and ROC curve analysis were performed
using SPSS 16.0 software.3. Results and discussion
3.1. LC separation
This ion-pair RP-HPLC method enabled the measurement of 12
nucleotides (ADP, AMP, UDP, GDP, GMP, CTP, dCTP, UTP,
dGTP, dUTP, ATP and dATP) in one run. Nucleotides are
hydrophilic and anionic compounds with a negatively charged
phosphate group and a ribose basic group. Since the polarity
increases with the number of phosphate groups, nucleoside
triphosphates, unlike nucleoside mono- and diphosphates, are
weakly retained on reversed-phase HPLC chromatography with a
conventional mobile phase40,41. Conversely, when the ion pairing
agent was added, nucleoside diphosphates were retained better
than mono-phosphates but more weakly than nucleoside tripho-
sphates. The separation is based on the formation of ion pair(s)
between the positively charged ion-pair reagent and the negatively
charged nucleotide.
Many factors can inﬂuence the separation of nucleotides, such
as ion pairing agents, organic modiﬁers and pH, which are critical
and should to be optimized to obtain good retention and peak
shape. Many studies have reported a variety of cationic ion species
to form ion-pair complexes, such as tetrabutylammonium hydroxide
used in previous studies for UV-coupled separation methods42.
The concentration range of tetrabutylammonium hydroxide wasreported as 2–10 mM with a high salt concentration of 10–50 mM.
In this study, the concentration of ion pair reagent was 8 mM and
proved optimal. For pH, it was showed that the compounds were
barely retained on the stationary phase and were easily eluted at
similar times at pH 343. Moreover, diphosphate and triphosphate
nucleosides were unstable and likely to lose one or two phosphate
groups at this pH44. A pH of 6–7 was shown to given satisfactory
retention due to its contribution to phosphate ionization. Jia et al.36
explored the effect of different pH values of mobile phase (6.5–8.5)
on compound resolution and showed that better chromatographic
resolution was achieved at pH 7.
Cell lysis is the ﬁrst step in sample preparation. It is important
to block the metabolism of nucleotides immediately by stopping
the enzymatic activities at low temperature. Biological samples
present high levels of proteins, making the determination of
nucleotides difﬁcult. The most common procedure to extract
nucleotides was protein precipitation. Several publications
reported trichloroacetic acid, perchloric acid or organic solvents
as precipitation reagents42,45. Trichloroacetic acid was less fre-
quently used than perchloric acid due to its poor compatibility with
MS, but perchloric acid caused co-precipitation with potassium
perchlorate and thus exerted a negative effect on the retention
behavior of nucleotides, causing material to be lost during the
sample preparation procedure in ion-pair chromatography8. We
attempted to mix equal volume of 12% perchloric acid and
samples and ﬁlter out the precipitates, but the ATP peak split into
two components after several injections, which may indicate
interference by polar compounds retained in the samples. After
acid extraction, the extracts were neutralized with a basic solution
to obtain a neutral pH, such as KOH, K2HPO4, K2CO3. Finally,
we adopted 6% trichloroacetic acid as the extraction reagent to
lyse the cells, followed by neutralization with 0.5 M KOH prior to
the analysis. This method allowed the simultaneous determination
of nucleotides in cell extracts.
3.2. Method validation
Representative HPLC chromatograms of 6% trichloroacetic acid
extract solution, a standard mixture of 12 nucleotides, and an
extracted cell sample are shown in Fig. 1. We identiﬁed all
analytes using the retention time established by the standards. As
observed in Fig. 1a, the extraction reagent did not interfere with
the analyte peaks, showing the satisfactory speciﬁcity of the
method. All analyte peaks were completely separated, and no
co-elution was observed (Fig. 1b). Calibration curves were
obtained by using linear regression analysis of six-point concen-
tration curves. The regression equation, linear range and correla-
tion coefﬁcient (r2) are given in Table 1 with LOD and LOQ
analysis of the 12 analytes. As shown in Table 2, the recovery
ranged 87.5–98.2%, suggesting an acceptable level using this
method; the mean intra- and inter-day precision was below 3.9%
and 4.9%, respectively. RSD of all compounds was less than 4.7%
in the stability test, showing that the samples were stable during
the analytical cycle.
3.3. Nucleotides pool size of cell lines
We applied an external calibration method with aqueous standards
to prepare calibration curves as previously described29. In this
study, the cell lines were harvested and extracted in their
exponential growth phase and analyzed according to the method
C. Zhang et al.258described above. The levels of analytes in the samples were
calculated from the calibration curves. The intracellular content of
each nucleotide was expressed as μg/108 cells, as shown in
Tables 3 and 4. From the results, we found that the pool sizesFigure 1 Representative chromatograms of 6% trichloroacetic acid
extract solution (a), standard mixture (b) and cell extract (c). 1, AMP;
2, UDP; 3, GDP; 4, GMP; 5, CTP; 6, ADP; 7, dCTP; 8, UTP; 9,
dUTP; 10, dGTP; 11, ATP; 12, dATP.
Table 1 Representative regression equation, linear range, LOQ and
Nucleotide Regression equation r2
AMP Y¼3.400 104X+7.438 103 0.9994
UDP Y¼1.981 104X−3.032 103 0.9999
GDP Y¼2.119 104X−1.319 104 0.9989
GMP Y¼1.997 104X+1.422 103 0.9977
CTP Y¼1.568 104X+0.787 103 0.9998
ADP Y¼3.047 104X−6.028 103 0.9996
dCTP Y¼1.224 104X−2.444 103 0.9993
UTP Y¼1.425 104X−1.140 104 0.9993
dUTP Y¼1.211 104X+2.482 103 0.9968
dGTP Y¼8.796 104X+6.355 103 0.9987
ATP Y¼3.281 104X−3.465 104 0.9993
dATP Y¼2.937 104X−6.446 102 0.9970varied from one cell line to another. We found that the RN levels
in each cell line were higher than those of the dRNs and that the
level of NTP present in normal cells was lower than that in most of
the tumor cell lines except for SGC7901, HepG2 and HT1080.
This result is probably associated with the degree of cell
proliferation and differentiation. A549 cells had the highest
intrinsic ATP, CTP and GDP levels, while the least amount of
NTPs was found in normal cells. SGC7901 cells had the highest
AMP, ADP and dGTP levels; HepG2 cells had the highest UDP
and UTP levels and the lowest dGTP pools. The highest levels of
dCTP and dUTP were found in normal cells, whereas MCF10A
cells expressed the lowest concentration of dATP. As for the
lowest levels of AMP, UDP, GDP and ADP, they were all found
in tumor cells.3.4. Statistics and analysis
To better differentiate normal cells from tumor cells, the unsupervised
chemometric method PCA was performed to evaluate and classify the
samples based on the content of the 12 nucleotides. SIMCAP-11.5
software was used to perform the multivariate analysis of the data sets.
The PCA score plots of the ﬁrst two principal components indicated
that the samples clustered into two groups (Fig. 2), revealing that
normal cell samples were well discriminated from tumor cell samples.
It is particularly evident in the score plots of normal cell lines that the
normal cells were relative dispersed, which is probably due to the early
stages of cell differentiation and a diversity of metabolic regulation. As
for the tumor cells, they were differentiated from the normal cells by
relatively higher differentiation. The metabolites that contributed to
sample clustering are revealed in the respective block loading plot
(Fig. 3), including AMP, UTP, GMP, CTP, UDP and ATP. We further
utilized one-way analysis of variance (One-way ANOVA) for each
variable. Since it was a problem of multiple comparisons, the threshold
for signiﬁcance, P-value, was adjusted downward by setting the false
discovery rate to Po0.05. Samples from normal cells were chosen as a
control group to indicate the selectivity of nucleosides for tumor cells.
The metabolite pool used to discriminate between normal and tumor
cells revealed six metabolites, namely AMP, UDP, CTP with a
signiﬁcant difference in levels at Po0.05; ATP, UTP and GMP were
signiﬁcant at Po0.01. This analysis revealed that the content of AMP,
UTP, ATP, GMP was signiﬁcantly higher in tumor cells. This ﬁnding
provides a theoretical basis to identify biochemical markers between
tumor and normal cells.LOD of the method.
Linear range (μg/mL) LOQ (ng/mL) LOD (ng/mL)
0.1060–21.20 70.67 42.40
0.2505–25.05 166.7 100.0
0.998–49.90 99.6 39.92
0.0998–10.24 66.53 33.27
0.2100–42.00 140.0 84.00
0.2528–50.55 125.1 50.06
0.4380–21.90 438.0 175.2
0.2675–42.80 178.3 107.0
0.0534–5.340 53.40 21.36
0.05772–2.861 38.48 11.44
1.032–51.60 68.80 41.20
0.04027–2.014 26.84 16.11
Table 2 The data of recovery, precision and stability for analysis of 12 nucleotides.
Nucleotide Recoverya (n¼3) Precision (% RSD) Stability (% RSD, n¼6)
High (%) Medium (%) Low (%) RSD (%) Intra-day (n¼3) Inter-day (n¼9)
AMP 94.374.11 94.873.80 95.572.36 3.2 1.0–2.4 2.9–4.9 1.5
UDP 92.073.13 90.873.90 97.070.90 4.2 1.3–3.5 3.1–4.1 3.1
GDP 89.771.17 87.572.05 88.471.76 2.0 1.8–2.9 3.0–3.8 4.5
GMP 94.974.76 92.270.85 93.274.97 3.9 2.3–3.1 2.8–4.9 4.0
CTP 94.973.18 97.672.82 94.876.43 4.2 1.0–2.9 1.1–3.4 4.7
ADP 92.273.24 95.974.76 97.173.47 4.2 2.0–3.7 2.3–4.6 4.4
dCTP 93.770.21 88.972.66 90.170.99 2.8 1.5−2.9 1.9–3.5 3.1
UTP 90.076.89 91.373.17 95.170.45 4.8 1.2–3.9 1.4–4.5 4.5
dUTP 93.572.43 96.372.91 90.973.59 3.8 1.4–3.0 3.1–4.7 2.9
dGTP 89.572.23 87.771.56 88.771.08 1.9 1.7−3.0 2.0–3.4 3.8
ATP 98.270.91 94.371.85 93.874.97 3.5 1.7–3.9 1.9–4.2 4.1
dATP 90.573.75 89.972.81 89.971.95 2.8 2.7−3.1 2.9–4.7 2.1
aRecovery data of low, medium and high are expressed as mean7SD.
Table 3 Contents of 12 nucleotides in 12 tumor cell lines (μg/108 cells).
Cell line AMP UDP GDP GMP CTP ADP dCTP UTP dUTP dGTP ATP dATP
SGC7901 39.5/10.4 79.9/7.8 67.6/9.4 33.3/14.8 51.8/9.4 99/9.0 7.35/1.0 148/17.5 5.42/2.2 2.84/1.9 163/12.8 1.04/0.09
DU145 35.0/9.8 52.2/6.5 63.4/3.0 68.6/7.1 29.6/5.9 78.1/0.9 3.75/1.1 106/3.6 7.56/1.0 2.19/0.3 151/6.6 1.94/0.7
PC3 31.8/17.1 53.6/2.7 N.D. 44.0/1.9 34.1/2.1 50.1/0.9 6.80/1.2 159/13.1 N.D. 1.56/2.1 145/5.1 1.88/0.9
SKOV3 37.5/11.0 76.9/1.3 41.4/3.4 35.4/3.4 34.3/13.6 89/13.5 7.21/2.1 143/2.1 2.40/0.3 1.55/0.2 166/2.3 0.93/0.2
HT1080 30.5/4.7 79.9/9.4 69.4/2.1 30.8/4.3 49.2/17.9 84/16.5 5.98/10.7 204/40.6 7.26/0.8 1.44/0.7 135/16.3 1.24/0.5
Hela 38.9/3.7 69.1/4.6 58.3/3.0 41.9/11.3 47.4/8.6 51.3/2.0 2.59/2.6 113/20.9 9.1/3.7 1.90/0.5 189/18.7 2.64/0.9
KB 26.8/20.7 53.6/4.8 N.D. 44.5/5.3 34.6/6.2 N.D. 6.80/1.1 157/30.6 N.D. 1.60/1.6 145/17.4 1.95/1.3
A549 18.1/8.2 89/2.6 114/23.0 47.1/11.4 60.8/23.7 50.9/4.9 6.17/1.1 106/11.2 8.1/1.5 1.55/1.6 205/61.2 0.95/0.6
HepG2 25.8/11.1 93/30.0 57.6/34.8 48.8/31.0 36.8/36.8 86.2/9.1 N.D. 247/59.0 0.503/0.1 N.D. 170/17.1 0.719/0.9
A204 28.9/17.8 59.1/5.3 57.3/14.8 41.9/9.4 57.4/13.4 51.3/7.3 4.59/1.8 114/25.8 8.1/2.8 1.22/1.3 190/3.9 2.64/1.6
T47D 14.4/4.0 66.4/17.3 64.9/27.3 37.9/11.9 19.0/10.6 54.6/9.5 7.28/1.8 177/17.1 8.2/1.8 2.35/2.3 127/21.9 0.97/1.7
MCF7 14.2/11.3 69.1/16.1 73.2/13.8 35.7/12.8 21.1/9.0 49.2/10.5 8.23/0.5 99.2/10.1 7.78/3.3 2.74/1.3 104/54.5 1.03/0.7
Data are expressed as mean/SD, n¼3.
N.D.: Not detected.
Table 4 Contents of 12 nucleotides in 4 normal cell lines (μg/108 cells).
Cell line AMP UDP GDP GMP CTP ADP dCTP UTP dUTP dGTP ATP dATP
3T3L1 14.9/9.5 73.2/8.8 79.9/7.0 5.89/2.5 25.1/12.7 55.7/8.1 N.D. 9.8/2.4 N.D. 2.09/2.0 57.8/8.8 0.98/1.2
HRMC 8.01/8.1 17.6/9.9 96/27.7 15.7/3.8 3.92/1.9 57.3/15.5 1.90/1.7 107/44.4 5.17/1.3 1.98/2.7 104/45.8 0.91/0.1
LX2 21.0/7.8 59.0/12.8 26.9/6.1 10.8/4.8 31.9/8.3 37.2/9.1 1.39/5.6 N.D. N.D. 1.69/1.4 92.1/8.7 2.11/1.4
MCF10A 26.5/8.8 14.0/7.4 47.3/8.0 40.6/8.3 9.87/1.8 21.3/18.4 8.71/5.4 23.4/12.1 9.18/6.5 0.891/0.2 102/77.2 0.116/0.2
Data are expressed as mean/SD, n¼3.
N.D.: Not detected.
Targeted metabolic analysis of nucleotides in tumor cells 259In order to assess our candidate biomarkers, ROC curve analysis,
which is generally considered as the standard method for perfor-
mance assessment analysis, was performed using SPSS 16.0 with
associated conﬁdence intervals. Six metabolites with a signiﬁcance
of Po0.05 or 0.01(CTP, UDP, AMP, UTP, GMP and ATP) were
selected as variables. The ability of nucleotide levels to be used to
discriminate between normal and tumor cells by ROC curve
analysis is shown in Fig. 4. After the analysis, the AUC ranged
0.792–0.938, the sequence of which was ATP (0.979)4UTP(0.938)4CTP¼GMP (0.896)4AMP (0.812)4UDP (0.792).
These result show reasonable accuracy even though UDP had a
low AUC of 0.792. The AUCs of ATP and UTP were above 0.9,
revealing a high accuracy. This result supports the one-way
ANOVA analysis of ATP and UTP with a signiﬁcance of
Po0.01. As tumor cells are metabolically active, large amounts
of energy must be produced and consumed in the process of growth,
resulting in a substantial accumulation of ATP. UTP is an essential
substrate for the synthesis of RNA, as well as being used as a
Figure 2 The PCA scores plot of tumor (■) and normal cells (●).
Figure 3 The loading plot provides information on compounds
responsible for the clustering of normal and tumor cells. Tumor cells
were correlated with GMP, ATP, CTP, UTP, AMP and UDP marked
with ♦.
Figure 4 ROC curve of the ability of nucleotide metabolites to
discriminate normal cells from tumor cells.
C. Zhang et al.260special energy source like ATP. Thus, we speculate that ATP might
be the best potential biomarker in tumor cells. These screened
nucleotide biomarkers may be useful for clinical cancer diagnosis.
Considerable research has shown that adenosine ribonucleotides
constituted the highest portion of the RNs pool12. It is recognized
that almost all energy-requiring processes in the cell are driven,
either directly or indirectly, by hydrolysis of the acid anhydridebonds in ATP, yielding ADP or AMP. The determination of
energy charge (EC¼ [ATP]+0.5[ADP]/[ATP]+[ADP]+[AMP]) is
of great importance in the characterization of the energy status of
different cells. EC reﬂects the high-energy-bond content and the
conversion of high-energy-bonds between ATP, ADP and AMP in
biological systems. It is considered a quantitative measure of cell
energy status and an estimate of the balance between adenine
nucleotides. It also plays an important role in the regulation of the
catabolism of energy substances. Under normal physiological
conditions, the value of EC is between 0.7 and 1.0. When the
value is equal to 1, intracellular adenylate exists in the form of
ATP, while when the value is 0, all adenylates exist in the form of
AMP. A higher EC value means that metabolism is more vigorous.
In the present study, we found differences in the energy charge of
individual cells, but there was no signiﬁcant difference between
normal and tumor cells. The result indicates that SGC7901 cell has
a lower EC level (0.70) than normal cell lines and MCF7 cell have
the overall highest level (0.89). This observation may be partly
responsible for the speed of differentiation, growth, and the active
metabolic state of tumor cells. The distinction of EC between
malignant and normal cells may be attributed to the ATP synthase
activity in mitochondria or Na+–K+–ATPase involved in ATP
consumption and de novo purine synthesis46.
Variations in the pool sizes of these compounds is also probably
related to the expression of some key enzymes involved in their
metabolism. The association between cancer disease and venous
thromboembolic processes was reported in many studies. Daonati
and Falanga47 found that cancer patients exhibited increased platelet
activation and that the NTPDase (EC3.6.1.5, CD39), which was a
membrane-bound enzyme in platelets, was closely related to this
process. Zanini et al.48 found that the NTPDase uses ADP as a
substrate, resulting in a signiﬁcant decrease in ADP hydrolysis in
patients with lung cancer compared with the control group, while no
signiﬁcant difference ATP levels was found. Accordingly, the
association was reinforced between neoplastic diseases and enzymes
with the activity of adenine nucleotide hydrolysis. Obviously,
intracellular nucleotide levels were related to the extent of their release
to extracellular medium. It was reported that a change of nucleotide
levels was stimulated by cell mechanical perturbations, for instance,
shear stress, membrane stretch, medium, hyposmotic swelling and
hypoxia49. Numerous studies further suggested that the cystic ﬁbrosis
transmembrane conductance regulator (CFTR) and other members of
the super-family of ATP-binding cassette-transport proteins regulate
the associated ATP channel50. Tatur et al. 51 found that ATP release in
A549 cells, which was absent in cells loaded with the Ca2+ chelator
1,2-bis(2-aminophenoxy) ethane-N,N,N′,N′-tetraacetic acid, were
tightly correlated with intracellular Ca2+ elevations.
Not all of the compounds were found in all cell types. Some
deoxynucleoside triphosphates, such as deoxycytidine triphosphate,
were very low in cells. For instance, we did not detect dUTP in the
KB cell line. This is concordant with previous studies. Zhang et al.12
reported that dUTP, dCDP, dUDP and dGMP were not detectable in
PANC1, H1975, H23 and HepG2 cell lines. Huang et al.29 did not
detected dCTP and dATP in asriamycin-resistant human breast
adenocarcinoma cells. Thus, these compounds may be likely to be
biomarkers for speciﬁc cancer diseases.4. Conclusions
The developed ion-pair RP-HPLC method is a sensitive and
reproducible method to simultaneously measure 12 mono-, di- and
Targeted metabolic analysis of nucleotides in tumor cells 261triphosphate nucleosides in cells. It can be used to distinguish cancer
cells from normal cells, to provide targeted endogenous metabolites
images of different cells, and to study the alterations in nucleotide
pools in cells after external stimuli. We also applied PCA methodol-
ogy to deconvolute two interacting factors, and thereby obtained a
more interpretable model that clearly identiﬁed the metabolites that
contributed to the clustering as potential biomarkers for cancers. The
model revealed an obviously different proﬁle of nucleotide metabo-
lism between normal and tumor cells, demonstrating that abnormal
metabolism of nucleotides occurs in tumor cells. Six variables (AMP,
UDP, CTP with a signiﬁcance of Po0.05; ATP, UTP and GMP with
a signiﬁcance of Po0.01) were considered as potential biomarkers,
and the content of AMP, UTP, GMP, ATP were signiﬁcantly higher
in tumor cells. In combination with ROC curve analysis, ATP and
UTP were recognized as the best potential biomarkers in tumor cells.
These speciﬁc metabolites might have signiﬁcance in clinics for
diagnosis, grading in tumors, and are worthy of further exploration.Acknowledgments
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